Xipamide

Base Information

• Chemical Name: Xipamide
• CAS No.: 14293-44-8
• Deprecated CAS: 135274-05-4
• Molecular Formula: C15H15ClN2O4S
• Molecular Weight: 354.814
• Hs Code.: 2935009090
• European Community (EC) Number: 238-216-4
• UNII: 4S9EY0NUEC
• DSSTox Substance ID: DTXSID5023744
• Nikkaji Number: J8.494H
• Wikipedia: Xipamide
• Wikidata: Q600951
• NCI Thesaurus Code: C87708
• Metabolomics Workbench ID: 154583
• ChEMBL ID: CHEMBL517199
• Mol file: 14293-44-8.mol

Synonyms:Xipamid;Xipamide

Chemical Property of Xipamide

Chemical Property:

• Melting Point: 255-256 °C
• Refractive Index: 1.652
• PKA: pKa 4.75±0.04(0.4% MeOH in H2O) (Uncertain)
• PSA: 117.87000
• Density: 1.477 g/cm³
• LogP: 4.41620
• Storage Temp.: Refrigerator
• Solubility.: DMSO: soluble20mg/mL, clear
• Water Solubility.: 58mg/L(25 oC)
• XLogP3: 2.9
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 3
• Exact Mass: 354.0441058
• Heavy Atom Count: 23
• Complexity: 526

Purity/Quality:

99%, ^*data from raw suppliers

Xipamide ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=C(C(=CC=C1)C)NC(=O)C2=CC(=C(C=C2O)Cl)S(=O)(=O)N
• Recent ClinicalTrials: Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis
• Uses: Xipamide is a diuretic and antihypertensive agent.
• Therapeutic Function: Diuretic, Antihypertensive
• Clinical Use: Thiazide diuretic: Hypertension Oedema
• Drug interactions: Potentially hazardous interactions with other drugs Analgesics: increased risk of nephrotoxicity with NSAIDs; antagonism of diuretic effect. Anti-arrhythmics: hypokalaemia leads to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised. Antibacterials: avoid administration with lymecycline. Antidepressants: increased risk of hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics. Antiepileptics: increased risk of hyponatraemia with carbamazepine. Antifungals: increased risk of hypokalaemia with amphotericin. Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotension with postsynaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol. Antipsychotics: hypokalaemia increases risk of ventricular arrhythmias with amisulpride; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide - avoid concomitant use. Atomoxetine: hypokalaemia increases risk of ventricular arrhythmias. Cardiac glycosides: increased toxicity if hypokalaemia occurs. Ciclosporin: increased risk of nephrotoxicity and possibly hypomagnesaemia. Cytotoxics: increased risk of ventricular arrhythmias due to hypokalaemia with arsenic trioxide; increased risk of nephrotoxicity and ototoxicity with platinum compounds. Lithium excretion reduced (increased toxicity).

Technology Process of Xipamide

There total 1 articles about Xipamide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

→ xipamide (14293-44-8)

Guidance literature:

Reference yield: 98.0%

uranyl nirate hexahydrate + xipamide (14293-44-8) → [UO2(4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoylbenzamide)2]*3H2O

Guidance literature:

With sodium hydroxide; In water; acetone; at 20 ℃; for 72h;

DOI:10.1134/S1070363218040229

Reference yield: 95.0%

titanium(III) chloride + xipamide (14293-44-8) + water (7732-18-5) → [Ti(4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoylbenzamide)2(H2O)2]Cl

Guidance literature:

With sodium hydroxide; In acetone; at 20 ℃; for 72h;

DOI:10.1134/S1070363218040229

Refernces